8-K: Arcturus: CF Drug Progress, Vaccine BLA Faces Setback

Arcturus Therapeutics announced encouraging interim Phase 2 results for its cystic fibrosis therapy ARCT-032 but faced a significant delay and new data requirements for its KOSTAIVE COVID-19 vaccine BLA submission to the FDA.

Summary

• Interim Phase 2 results for ARCT-032, an investigational inhaled mRNA therapy for cystic fibrosis, showed it was generally safe and well-tolerated in Class I CF adults.
• Four out of six Class I CF participants treated with 10 mg ARCT-032 daily for 28 days exhibited a reduction in mucus plug number and mucus volume, as observed via AI-enhanced high-resolution CT scans.
• An exploratory post hoc analysis of lung function (percent predicted FEV1, ppFEV) suggested improvements in four of six Class I CF participants, with an average absolute increase of 3.8% and a relative increase of 5.1% from baseline to Day 42.
• The Company plans to initiate a 12-week safety and preliminary efficacy study for ARCT-032 in up to 20 CF participants in the first half of 2026.
• Arcturus filed a lawsuit on September 23, 2025, against AbbVie Inc., Capstan Therapeutics, Inc., and others for trade secret misappropriation and breach of contract.
• CSL Seqirus submitted a Marketing Authorization Application (MAA) for KOSTAIVE (self-amplifying mRNA COVID-19 vaccine) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in June 2025, with approval expected in the first quarter of 2026.
• The U.S. Food and Drug Administration (FDA) requested a delay in the Biologics License Application (BLA) submission for KOSTAIVE on September 5, 2025, and subsequently informed the Company on October 14, 2025, that additional data from a clinical endpoint efficacy study will be required for BLA submission.
• 侬,
• positives": [ "ARCT-032 was generally safe and well-tolerated in the Phase 2 interim study.
• Meaningful trends of clinical activity were observed, with 4 out of 6 Class I CF participants showing reductions in mucus plug number and mucus volume after 28 days of ARCT-032 treatment.
• Exploratory lung function analysis (ppFEV) suggested potential improvements in 4 of 6 Class I CF participants, with an average absolute increase of 3.8% and a relative increase of 5.1%.
• CSL Seqirus submitted a Marketing Authorization Application for KOSTAIVE in the UK in June 2025, with approval anticipated in the first quarter of 2026.

Sentiment

Score: 5

Explanation: The positive interim clinical data for ARCT-032 in cystic fibrosis is encouraging, especially for an unmet medical need. However, this is significantly offset by the major regulatory setback for the KOSTAIVE COVID-19 vaccine in the US, which introduces substantial delays and uncertainty for a key partnered product. The legal proceedings add another layer of risk.

Negatives

• One serious adverse event (SAE) occurred in an ARCT-032 participant, though the Data Monitoring Committee found no convincing evidence of relation to ARCT-032.
• Initial FEV1 analysis did not demonstrate meaningful improvement, requiring a post hoc exploratory analysis to suggest potential benefits.
• The U.S. FDA requested a delay in the Biologics License Application (BLA) submission for KOSTAIVE.
• The FDA now requires additional data from a clinical endpoint efficacy study for KOSTAIVE BLA, which was not previously deemed necessary for a single-dose indication.

Risks

• Uncertainty regarding the timing and likelihood of regulatory approval for KOSTAIVE in the UK and the US.
• The new FDA requirement for a clinical endpoint efficacy study for KOSTAIVE will significantly delay its BLA submission and potential market entry in the US.
• Clinical study results, particularly exploratory analyses, may not be predictive of future clinical results or sufficient for regulatory approval.
• Ongoing legal proceedings against AbbVie Inc., Capstan Therapeutics, Inc., and others introduce litigation risk and potential financial impact.
• The ability to continue enrolling participants in the Phase 2 study of ARCT-032 and the success of future clinical trials are subject to uncertainties.

Future Outlook

The Company plans to initiate a 12-week safety and preliminary efficacy study for ARCT-032 in up to 20 CF participants in the first half of 2026. Approval of the KOSTAIVE MAA in the UK is expected in the first quarter of 2026. The Company and CSL Seqirus are currently evaluating the new FDA requirements for the KOSTAIVE BLA submission.

Management Comments

• Juergen Froehlich, MD, Chief Medical Officer: "We are particularly encouraged by the early signals of mucus plug reduction in Class I CF participants treated with ARCT-032 because Class I CF individuals do not produce CFTR and therefore do not respond to available CFTR modulator therapy. The AI-enhanced lung imaging data before and after treatment with ARCT-032, supported by exploratory FEV1 lung function data analysis in this short-term study, warrant further investigation at higher doses and longer treatment durations. We look forward to initiating our 12-week study in the first half of next year for this promising therapeutic intended to address significant unmet medical need."
• Dr. Harm Tiddens, Professor Emeritus of Pediatric Pulmonology: "The early imaging data from this trial are encouraging. Seeing a trend towards a reduction in mucus plugs and volume after only 28 days of treatment suggests biological activity. Mucus plug reduction can be followed with longer-term lung function improvements over multi-month treatment durations. These findings suggest that ARCT-032 may be addressing the underlying pathology of cystic fibrosis in a meaningful way."

Industry Context

The interim ARCT-032 data is significant for Class I CF patients who currently lack effective CFTR modulator therapies due to their underlying mutations, addressing a high unmet medical need. The regulatory setback for KOSTAIVE highlights the evolving and stringent requirements for COVID-19 vaccines, potentially impacting market entry and competition in the infectious disease vaccine landscape.

Legal Proceedings

• Filed a lawsuit against AbbVie Inc., Capstan Therapeutics, Inc., and other defendants in the United States District Court for the Southern District of California on September 23, 2025.
• The lawsuit asserts claims for trade secret misappropriation and breach of contract.
• The current deadline for defendants to respond to the complaint is December 1, 2025.

Stakeholder Impact

• Shareholders: Mixed impact; positive clinical progress for ARCT-032 offers future potential, but the significant delay and increased requirements for KOSTAIVE's US BLA create substantial uncertainty and could negatively impact near-term revenue expectations and stock performance. Legal proceedings add risk.
• Cystic Fibrosis Patients (Class I): Encouraging early data for ARCT-032 suggests a potential new therapeutic option for a population with high unmet medical need, offering hope for improved outcomes.
• COVID-19 Vaccine Market/Patients: The delay in KOSTAIVE's US BLA means a longer wait for this self-amplifying mRNA vaccine to potentially become available in the US market.
• CSL Seqirus (Partner): The FDA's new requirements for KOSTAIVE BLA necessitate a re-evaluation of development strategy and timelines, impacting their partnered vaccine program.

Next Steps

• Continue enrollment in the third cohort (15 mg) of the ARCT-032 Phase 2 study.
• Initiate a 12-week safety and preliminary efficacy study for ARCT-032 in up to 20 CF participants in the first half of 2026.
• Evaluate the new FDA requirements for the KOSTAIVE BLA submission with CSL Seqirus.
• Await UK MHRA approval for KOSTAIVE MAA, expected in Q1 2026.
• Defendants to respond to the Company's lawsuit by December 1, 2025.

Key Dates

Recommendation

The filing presents a mixed bag of news. The interim Phase 2 data for ARCT-032 in cystic fibrosis is genuinely encouraging, particularly for Class I patients who lack effective treatments, suggesting biological activity and potential for a significant therapeutic. This positive development, however, is overshadowed by a major regulatory setback for the KOSTAIVE COVID-19 vaccine in the US, where the FDA has requested a delay and now requires an additional clinical endpoint efficacy study. This significantly pushes back the timeline for a key revenue-generating product and introduces considerable uncertainty. The ongoing lawsuit adds another layer of risk. Given these conflicting signals – a promising early-stage asset versus a substantial delay for a late-stage partnered product – a "hold" recommendation is appropriate as investors await further clarity on the KOSTAIVE regulatory path and more mature data from ARCT-032.

Keywords

Arcturus Therapeutics, ARCT-032, Cystic Fibrosis, mRNA therapy, KOSTAIVE, COVID-19 vaccine, FDA BLA, MHRA MAA, Clinical Trial, Phase 2, Regulatory Delay, Trade Secret Misappropriation, Biotechnology, Pharmaceuticals, Rare Disease, Vaccines